BRN (ASX) NANOSE &amp; SNIFFPHONE

Originally posted by Fact Finder: ↑

The thing that needs to be realised by recent arrivals is that NaNose and Technion have been on this journey of having their sensor technology for viral and other disease detection approved for many years starting full steam if memory serves correctly in about 2010. They were at that time part of a European consultative group which involved Siemens Medical. The group had two aims.

The first was to prove the sensor technology and the second was to create the SniffPhone. The involvement of Siemens Medical was to provide if possible the technology capable of implementing the NaNose Technion sensors in this hand held device they named SniffPhone.

Again if memory serves me it was late 2018 early 2019 when Siemens Medical admitted defeat in that their efforts had only reached the point where they were able to provide sufficient processing power on device to detect bad breath. This had taken the best part of seven years.

Sometime in 2019 Professor Hiack became aware of Brainchip and AKIDA technology. In my opinion it most likely resulted from him reading the results of the Brainchip ADE, Enose performing state of the art analysis of the 20 gas data set using only 200 neurons in 3 seconds.

The point of this little history lesson is that the real issue for NaNose is the testing of its sensor. The FDA back sometime between 2010 and 2020 agreed to a trial for the detection of cancer which required NaNose to test 10,000 people and as at the last information on this testing which came to light the beginning of 2021 they had tested more than 7,000 people as part of this trial to satisfy the FDA and had about 3,000 to go.

The use of AKIDA to test the data from the sensor is less of an issue as it is simply taking all the collected data from the sensor and feeding it to AKIDA which is what was done in the Wuhan trials in 2020. NaNose used their sensor on the trial participants and gathered the data on a laptop and then sent the full data set to Perth for Peter van der Made and team to process with AKIDA. This was done very quickly and the results were then compared with the PCR test results from Wuhan and it showed AKIDA was detecting at ninety four point something percent using the engineering AKD1000 which as we know with the new commercial AKD1000 is now running at above 98% accuracy compared with the PCR test which achieves in the order of 90% accuracy.

So can various people please try and understand that testing whether AKIDA can do the job is not and never will be the issue, the cause of any delay or of any concern whatsoever is the required FDA testing of the NaNose sensors.

ONCE NANOSE GATHERS ALL THE DATA IT CAN BE SENT TO BRAINCHIP AND THEN RUN THROUGH AKIDA IN DOUBLE QUICK TIME. THE SLOW BIT IS NANOSE GATHERING THE DATA AND HAVING BACK ALL THE PCR TEST RESULTS SO THEY CAN COMPARE THE NANOSE AKIDA RESULTS WITH THOSE FROM THE PCR TESTS WHICH ARE ACTING AS THE CONTROL.

The only complication is that the FDA requires the same processor that is used for the trials to be used in the final device. To the extent there was a delay down to Brainchip it was alleviated by the release and successful testing of the AKD1000 commercial chip. If you were invested here you might recall the criticism by some of how long was being taken over this testing. It never occurred to those who were being critical no doubt for the usual reasons that this was all part of Brainchip's obligation to the FDA as part of the NaNose trials.

As Peter van der Made said at the AGM it is all up to NaNose Brainchip has no control over the gathering of the clinical data and the PCR control results.

As the former CEO Mr. Dinardo said AKIDA recognises patterns. You can give it any pattern and it will identify it. Data provided by NaNose is just another pattern like voice, temperature, pressure, vision, vibration etc; but it does it all on chip at ludicrously low power unnconnected with incredibly low latency.

My opinion only DYOR
FF

AKIDA BALLISTA

Expand

Thanks for the recap FF, there's nothing we can do about rushing the time line for nanose, it takes as long as it takes and it's up to nanose to get it all happening

No.	Vol.	Price($)
33	1897534	19.0¢

No.

Vol.

Price($)

1897534

19.0¢

Price($)	Vol.	No.
19.5¢	32198	10

Price($)

Vol.

No.

19.5¢

32198

No.	Vol.	Price($)
33	1897534	0.190
25	1028498	0.185
27	809560	0.180
23	816331	0.175
36	1296492	0.170

No.

Vol.

Price($)

1897534

0.190

1028498

0.185

809560

0.180

816331

0.175

1296492

0.170

Price($)	Vol.	No.
0.195	186169	13
0.200	1336301	11
0.205	1198580	15
0.210	1193604	28
0.215	540193	10

Price($)

Vol.

No.

0.195

186169

0.200

1336301

0.205

1198580

0.210

1193604

0.215

540193

(20min delay)
Last 19.5¢		Change 0.000(0.00%)		Mkt cap ! $382.6M

Open	High	Low	Value	Volume
19.5¢	20.5¢	19.0¢	$1.442M	7.234M

Thanks for the recap FF, there's nothing we can do about...

Legacy hits high-grade gold, silver and copper through drilling at NSW's Bauloora

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the recap FF, there&apos;s nothing we can do about...

Top Stories

Legacy hits high-grade gold, silver and copper through drilling at NSW's Bauloora

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the recap FF, there's nothing we can do about...